Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pin-Nan Cheng

Showing results (81-90 of 137) with videos related to

Pageof 14
Sort By:
Journal of the Formosan Medical Association = Taiwan Yi Zhi|November 19, 2018
Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE studyChen-Hua Liu, Ming-Lung Yu, Cheng-Yuan Peng, et al.
The Kaohsiung Journal of Medical Sciences|January 10, 2023
Clinical prognosis of surgical resection versus transarterial chemoembolization for single large hepatocellular carcinoma (≥5 cm): A propensity score matching analysisPei-Min Hsieh, Pojen Hsiao, Yaw-Sen Chen, et al.
Alimentary Pharmacology & Therapeutics|October 27, 2018
Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in TaiwanChen-Hua Liu, Ming-Lung Yu, Cheng-Yuan Peng, et al.
Journal of Gastroenterology and Hepatology|February 20, 2019
Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infectionLai Wei, Hiromitsu Kumada, Ponni V Perumalswami, et al.
Viruses|November 27, 2021
Drug Resistance Profile and Clinical Features for Hepatitis C Patients Experiencing DAA Failure in TaiwanChun-Ming Hong, You-Yu Lin, Chun-Jen Liu, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|February 7, 2023
TASL, TADE, and DAROC consensus for the screening and management of hepatitis C in patients with diabetesMing-Lung Yu, Chih-Yuan Wang, Mei-Hsuan Lee, et al.
Hepatology International|July 26, 2015
Aligning to the sample-specific reference sequence to optimize the accuracy of next-generation sequencing analysis for hepatitis B virusWen-Chun Liu, Chih-Peng Lin, Chun-Pei Cheng, et al.
The Journal of Infectious Diseases|May 13, 2020
High Risk of Clinical Relapse in Patients With Chronic Hepatitis B Virus Infection After Cessation of Prophylactic Antiviral Therapy for Rituximab-Containing ChemotherapyWei-Yuan Chang, Yen-Cheng Chiu, Fang-Wei Chiu, et al.
Cancer Immunology, Immunotherapy : CII|January 7, 2021
Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosisHong-Ming Tsai, Meng-Zhi Han, Yih-Jyh Lin, et al.
Plos One|September 15, 2015
Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected PatientsChi-Chieh Yang, Wei-Lun Tsai, Wei-Wen Su, et al.
Pageof 14

Showing results (81-90 of 137) with videos related to

Sort By:
Pageof 14
Journal of the Formosan Medical Association = Taiwan Yi Zhi|November 19, 2018
Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE studyChen-Hua Liu, Ming-Lung Yu, Cheng-Yuan Peng, et al.
The Kaohsiung Journal of Medical Sciences|January 10, 2023
Clinical prognosis of surgical resection versus transarterial chemoembolization for single large hepatocellular carcinoma (≥5 cm): A propensity score matching analysisPei-Min Hsieh, Pojen Hsiao, Yaw-Sen Chen, et al.
Alimentary Pharmacology & Therapeutics|October 27, 2018
Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in TaiwanChen-Hua Liu, Ming-Lung Yu, Cheng-Yuan Peng, et al.
Journal of Gastroenterology and Hepatology|February 20, 2019
Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infectionLai Wei, Hiromitsu Kumada, Ponni V Perumalswami, et al.
Viruses|November 27, 2021
Drug Resistance Profile and Clinical Features for Hepatitis C Patients Experiencing DAA Failure in TaiwanChun-Ming Hong, You-Yu Lin, Chun-Jen Liu, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|February 7, 2023
TASL, TADE, and DAROC consensus for the screening and management of hepatitis C in patients with diabetesMing-Lung Yu, Chih-Yuan Wang, Mei-Hsuan Lee, et al.
Hepatology International|July 26, 2015
Aligning to the sample-specific reference sequence to optimize the accuracy of next-generation sequencing analysis for hepatitis B virusWen-Chun Liu, Chih-Peng Lin, Chun-Pei Cheng, et al.
The Journal of Infectious Diseases|May 13, 2020
High Risk of Clinical Relapse in Patients With Chronic Hepatitis B Virus Infection After Cessation of Prophylactic Antiviral Therapy for Rituximab-Containing ChemotherapyWei-Yuan Chang, Yen-Cheng Chiu, Fang-Wei Chiu, et al.
Cancer Immunology, Immunotherapy : CII|January 7, 2021
Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosisHong-Ming Tsai, Meng-Zhi Han, Yih-Jyh Lin, et al.
Plos One|September 15, 2015
Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected PatientsChi-Chieh Yang, Wei-Lun Tsai, Wei-Wen Su, et al.
Pageof 14